- 1.
Sjöqvist F. A pharmacokinetic approach to the treatment of depression. Int Pharmacopsychiatry 1971; 6: 147–69. [PubMed][CrossRef]
- 2.
Aronson JK, Hardman M. ABC of monitoring drug therapy. Measuring plasma drug concentrations. BMJ 1992; 305: 1078–80. [PubMed][CrossRef]
- 3.
Bengtsson F. Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau". Ther Drug Monit 2004; 26: 145–51. [PubMed][CrossRef]
- 4.
Andersen S, Refsum H, Tanum L. Bruk av psykofarmaka–bør serumkonsentrasjonen kontrolleres? Tidsskr Nor Lægeforen 2004; 124: 2362–4. [PubMed]
- 5.
Solberg DK, Haslemo T, Refsum H. Psykofarmakologisk poliklinikk. Tidsskr Nor Legeforen 2012; 132: 1065–7. [PubMed][CrossRef]
- 6.
Reis M, Aberg-Wistedt A, Agren H et al. Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Hum Psychopharmacol 2004; 19: 283–91. [PubMed][CrossRef]
- 7.
Reimers A. Trends and changes in the clinical use of lamotrigine. Pharmacoepidemiol Drug Saf 2009; 18: 132–9. [PubMed][CrossRef]
- 8.
Mårdby AC, Schiöler L, Sundell KA et al. Adherence to antidepressants among women and men described with trajectory models: a Swedish longitudinal study. Eur J Clin Pharmacol 2016; 72: 1381–9. [PubMed][CrossRef]
- 9.
Hov I, Bjartnes M, Slørdal L et al. Tas legemidler som foreskrevet? Tidsskr Nor Legeforen 2012; 132: 418–22. [PubMed][CrossRef]
- 10.
Sabate E. Adherence to long-term therapies. Evidence for action. Geneve: World Health Organization, 2003. https://apps.who.int/iris/bitstream/handle/10665/42682/9241545992.pdf Lest 16.4.2020.
- 11.
Hovstadius B, Astrand B, Petersson G. Dispensed drugs and multiple medications in the Swedish population: an individual-based register study. BMC Clin Pharmacol 2009; 9: 11. [PubMed][CrossRef]
- 12.
Farmakologiportalen. www.farmakologiportalen.no Lest 16.4.2020.
()